Funding round brings in $15M for Epitomics spinoff

05/23/2013 | MedCityNews.com

Apexigen, which specializes in developing new cancer drugs using rabbit-derived, humanized monoclonal antibodies, secured $15 million in an equity round. APX005, the California-based firm's lead drug candidate, is under development as a treatment for pancreatic cancer and other difficult-to-treat cancers.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI